158 related articles for article (PubMed ID: 31939351)
1. Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment.
Chelly S; Maulaz P; Bigot P; Azzouzi AR; Lebdai S
Asian J Androl; 2020; 22(5):454-458. PubMed ID: 31939351
[TBL] [Abstract][Full Text] [Related]
2. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
[TBL] [Abstract][Full Text] [Related]
3. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
[TBL] [Abstract][Full Text] [Related]
4. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
[TBL] [Abstract][Full Text] [Related]
5. [Erectile dysfunction evaluation after brachytherapy for low risk prostate adenocarcinoma: prospective study of patients with a baseline IIEF5>16].
Delage F; Perrouin-Verbe MA; Le Fur E; Papin G; Thoulouzan M; Malhaire JP; Pradier O; Fournier G; Valéri A
Prog Urol; 2015 Feb; 25(2):68-74. PubMed ID: 25497176
[TBL] [Abstract][Full Text] [Related]
6. Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes.
Lebdai S; Bigot P; Leroux PA; Berthelot LP; Maulaz P; Azzouzi AR
J Urol; 2017 Aug; 198(2):335-344. PubMed ID: 28322857
[TBL] [Abstract][Full Text] [Related]
7. Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study.
Rodriguez-Rivera JA; Rodriguez-Lay R; Zegarra-Montes L; Benzaghou F; Gaillac B; Azzouzi AR; Reis LO; Palma P
Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):632-638. PubMed ID: 29699883
[TBL] [Abstract][Full Text] [Related]
8. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
Azzouzi AR; Vincendeau S; Barret E; Cicco A; Kleinclauss F; van der Poel HG; Stief CG; Rassweiler J; Salomon G; Solsona E; Alcaraz A; Tammela TT; Rosario DJ; Gomez-Veiga F; Ahlgren G; Benzaghou F; Gaillac B; Amzal B; Debruyne FM; Fromont G; Gratzke C; Emberton M;
Lancet Oncol; 2017 Feb; 18(2):181-191. PubMed ID: 28007457
[TBL] [Abstract][Full Text] [Related]
9. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy.
Flegar L; Buerk B; Proschmann R; Propping S; Groeben C; Baunacke M; Herout R; Huber J; Thomas C; Borkowetz A
Eur Urol Focus; 2022 Jan; 8(1):121-127. PubMed ID: 33602642
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].
Lebdai S; Martin F; Bigot P; Azzouzi AR
Prog Urol; 2014 Nov; 24(14):911-4. PubMed ID: 25195031
[TBL] [Abstract][Full Text] [Related]
11. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.
Lebdai S; Villers A; Barret E; Nedelcu C; Bigot P; Azzouzi AR
World J Urol; 2015 Jul; 33(7):965-71. PubMed ID: 25614256
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Radical Prostatectomy: A Randomized Clinical Trial.
Baccaglini W; Pazeto CL; Corrêa Barros EA; Timóteo F; Monteiro L; Saad Rached RY; Navas A; Glina S
J Sex Med; 2020 Apr; 17(4):688-694. PubMed ID: 32007430
[TBL] [Abstract][Full Text] [Related]
13. WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice.
Neuschmelting V; Kim K; Malekzadeh-Najafabadi J; Jebiwott S; Prakash J; Scherz A; Coleman JA; Kircher MF; Ntziachristos V
Theranostics; 2018; 8(3):723-734. PubMed ID: 29344301
[No Abstract] [Full Text] [Related]
14. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
[TBL] [Abstract][Full Text] [Related]
15. Exploring the association between erectile rigidity and treatment adherence with sildenafil.
Mazzola CR; Deveci S; Teloken P; Mulhall JP
J Sex Med; 2013 Jul; 10(7):1861-6. PubMed ID: 23253943
[TBL] [Abstract][Full Text] [Related]
16. Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy-A review.
Kawczyk-Krupka A; Wawrzyniec K; Musiol SK; Potempa M; Bugaj AM; Sieroń A
Photodiagnosis Photodyn Ther; 2015 Dec; 12(4):567-74. PubMed ID: 26467273
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal shockwave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study.
Yee CH; Chan ES; Hou SS; Ng CF
Int J Urol; 2014 Oct; 21(10):1041-5. PubMed ID: 24942563
[TBL] [Abstract][Full Text] [Related]
18. Penile Low Intensity Shock Wave Treatment is Able to Shift PDE5i Nonresponders to Responders: A Double-Blind, Sham Controlled Study.
Kitrey ND; Gruenwald I; Appel B; Shechter A; Massarwa O; Vardi Y
J Urol; 2016 May; 195(5):1550-1555. PubMed ID: 26694904
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.
Chevalier S; Cury FL; Scarlata E; El-Zayat E; Hamel L; Rocha J; Zouanat FZ; Moussa S; Scherz A; Elhilali M; Anidjar M
J Urol; 2013 Nov; 190(5):1946-53. PubMed ID: 23680311
[TBL] [Abstract][Full Text] [Related]
20. Recovery of Baseline Erectile Function in Men Following Radical Prostatectomy for High-Risk Prostate Cancer: A Prospective Analysis Using Validated Measures.
Sridhar AN; Cathcart PJ; Yap T; Hines J; Nathan S; Briggs TP; Kelly JD; Minhas S
J Sex Med; 2016 Mar; 13(3):435-43. PubMed ID: 26944466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
